OBJECTIVES: A retrospective analysis was performed on patients treated for lung oligo-metastatic disease from radio-resistant histology groups. METHODS: The primary end point was local control (LC), secondary end points were overall survival (OS) and progression free survival (PFS). Toxicity was scored according to CTCAE 4.03. RESULTS: 200 patients were analyzed: 49.5% of the cases derived from colorectal primary tumors, 20.5% from sarcomas, 12.0% from renal cell carcinoma and the rest from other mixed origin. The mean follow-up was 24.2 months. LC at 1 and 2 years was 91, 84.9%. Primary histology and the presence of extra-pulmonary disease had a significant impact on LC. OS at 1 and 2 years was 88.7, 65.4%. Primary histology, disease free interval, presence of extra-pulmonary disease, number of irradiated lung lesions and age showed a correlation with prognosis at univariate analysis. PFS at 1 and 2 years was 84, 57.7%. The presence of extra-pulmonary disease and the number of irradiated lung lesions correlated with prognosis. Treatment was well tolerated with no G3-4 acute or late toxicity recorded. CONCLUSION: Colorectal metastases showed a higher rate of local relapse. However, the factors mostly influencing prognosis were the presence of extra-pulmonary disease and the number of lung lesions.
OBJECTIVES: A retrospective analysis was performed on patients treated for lung oligo-metastatic disease from radio-resistant histology groups. METHODS: The primary end point was local control (LC), secondary end points were overall survival (OS) and progression free survival (PFS). Toxicity was scored according to CTCAE 4.03. RESULTS: 200 patients were analyzed: 49.5% of the cases derived from colorectal primary tumors, 20.5% from sarcomas, 12.0% from renal cell carcinoma and the rest from other mixed origin. The mean follow-up was 24.2 months. LC at 1 and 2 years was 91, 84.9%. Primary histology and the presence of extra-pulmonary disease had a significant impact on LC. OS at 1 and 2 years was 88.7, 65.4%. Primary histology, disease free interval, presence of extra-pulmonary disease, number of irradiated lung lesions and age showed a correlation with prognosis at univariate analysis. PFS at 1 and 2 years was 84, 57.7%. The presence of extra-pulmonary disease and the number of irradiated lung lesions correlated with prognosis. Treatment was well tolerated with no G3-4 acute or late toxicity recorded. CONCLUSION:Colorectal metastases showed a higher rate of local relapse. However, the factors mostly influencing prognosis were the presence of extra-pulmonary disease and the number of lung lesions.
Authors: Simon S Lo; Bin S Teh; Nina A Mayr; Thomas E Olencki; Jian Z Wang; John C Grecula; Jiade J Lu; Robert D Timmerman Journal: Discov Med Date: 2010-09 Impact factor: 2.970
Authors: U Pastorino; M Buyse; G Friedel; R J Ginsberg; P Girard; P Goldstraw; M Johnston; P McCormack; H Pass; J B Putnam Journal: J Thorac Cardiovasc Surg Date: 1997-01 Impact factor: 5.209
Authors: Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Joseph K Salama; Michael D Hasselle; Steven J Chmura; Renuka Malik; Neil Mehta; Kamil M Yenice; Victoria M Villaflor; Walter M Stadler; Philip C Hoffman; Ezra E W Cohen; Philip P Connell; Daniel J Haraf; Everett E Vokes; Samuel Hellman; Ralph R Weichselbaum Journal: Cancer Date: 2011-10-21 Impact factor: 6.860
Authors: Andrew Yaeh; Tavish Nanda; Ashish Jani; Tzlil Rozenblat; Yasir Qureshi; Shumaila Saad; Jeraldine Lesser; Andrew B Lassman; Steven R Isaacson; Michael B Sisti; Jeffrey N Bruce; Guy M McKhann; Tony J C Wang Journal: J Neurooncol Date: 2015-08-02 Impact factor: 4.130
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Kamran A Ahmed; Jimmy J Caudell; Ghassan El-Haddad; Anders E Berglund; Eric A Welsh; Binglin Yue; Sarah E Hoffe; Arash O Naghavi; Yazan A Abuodeh; Jessica M Frakes; Steven A Eschrich; Javier F Torres-Roca Journal: Int J Radiat Oncol Biol Phys Date: 2016-04-08 Impact factor: 7.038
Authors: V Dell'Acqua; A Surgo; F Kraja; J Kobiela; Maria Alessia Zerella; P Spychalski; S Gandini; C M Francia; D Ciardo; C Fodor; A M Ferrari; G Piperno; F Cattani; S Vigorito; F Pansini; W Petz; R Orecchia; M C Leonardi; B A Jereczek-Fossa Journal: Clin Exp Metastasis Date: 2019-06-04 Impact factor: 5.150
Authors: Christopher Cao; Daniel Wang; David H Tian; Ashley Wilson-Smith; James Huang; Andreas Rimner Journal: J Thorac Dis Date: 2019-12 Impact factor: 2.895
Authors: Pranshu Mohindra; Amit Sawant; Robert J Griffin; Narottam Lamichhane; Erina Vlashi; Meng Xu-Welliver; Michael Dominello; Michael C Joiner; Jay Burmeister Journal: J Appl Clin Med Phys Date: 2019-02-22 Impact factor: 2.102
Authors: Hoon Sik Choi; Bae Kwon Jeong; Ki Mun Kang; Hojin Jeong; Jin Ho Song; In Bong Ha; Oh-Young Kwon Journal: Cancer Res Treat Date: 2020-07-21 Impact factor: 4.679